<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7409">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010475</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-4250</org_study_id>
    <secondary_id>2015-003908-23</secondary_id>
    <secondary_id>U1111-1173-8618</secondary_id>
    <nct_id>NCT03010475</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects</brief_title>
  <official_title>A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. Tha aim of this trial is to investigate the effect of
      oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the furosemide plasma concentration-time curve</measure>
    <time_frame>day 1, day 7, day 54</time_frame>
    <description>Based on sampling between 0 and 12 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the rosuvastatin plasma concentration-time curve</measure>
    <time_frame>day 2, day 8, day 55</time_frame>
    <description>Based on sampling between 0 and 96 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed furosemide plasma concentration</measure>
    <time_frame>day 1, day 7, day 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed rosuvastatin plasma concentration</measure>
    <time_frame>day 2, day 8, day 55</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Furosemide/Rosuvastatin/SNAC/Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Oral administration A total of three single doses.</description>
    <arm_group_label>Furosemide/Rosuvastatin/SNAC/Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Oral administration. A total of three single doses.</description>
    <arm_group_label>Furosemide/Rosuvastatin/SNAC/Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNAC</intervention_name>
    <description>Oral administration. A total of five single doses.</description>
    <arm_group_label>Furosemide/Rosuvastatin/SNAC/Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Oral administration. Once daily.</description>
    <arm_group_label>Furosemide/Rosuvastatin/SNAC/Semaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Male or female, aged 18-65 years (both inclusive) at the time of signing informed
             consent

          -  Body mass index (BMI) between 20.0-29.9 kg/m^2 (both inclusive)

          -  Considered to be generally healthy based on the medical history, physical
             examination, and the results of vital signs, electrocardiography and clinical
             laboratory tests performed during the screening visit, as judged by the investigator

        Exclusion Criteria:

          -  Smoker (defined as a subject who is smoking at least one cigarette or the equivalent
             per day)

          -  Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma
             in excess of 400 mL within the 3 months preceding screening

          -  History of major surgical procedures involving the stomach potentially affecting
             absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy,
             gastric bypass surgery)

          -  Have personal or family history of myopathy

          -  Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or
             fibrate

          -  Thyroid-Stimulating Hormone outside lower limit of normal minus 10 percent and upper
             limit of normal plus 10 percent

          -  Creatine kinase above 5 x upper limit of normal

          -  Asian subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR,1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 9, 2017</lastchanged_date>
  <firstreceived_date>January 3, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
